{"id":1581,"date":"2023-02-27T13:52:05","date_gmt":"2023-02-27T13:52:05","guid":{"rendered":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/ajouts-a-la-liste-des-essais-cliniques\/"},"modified":"2026-03-31T15:32:10","modified_gmt":"2026-03-31T15:32:10","slug":"additions-to-the-clinical-trials-list-2","status":"publish","type":"post","link":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/additions-to-the-clinical-trials-list-2\/","title":{"rendered":"Ajouts \u00e0 la liste des essais cliniques"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_empty_space][vc_column_text]<strong>POUR LES PATIENTS QUI N&rsquo;ONT PAS EU DE TRAITEMENTS M\u00c9DICAMENTEUX ANT\u00c9RIEURS<\/strong><\/p>\n<ul>\n<li><a href=\"\/trial\/a-study-of-belzutifan-pembrolizumab-versus-pembrolizumab-alone-for-patients-with-advanced-kidney-cancer\/\">Une \u00e9tude sur une combinaison de belzutifan et de pembrolizumab comparativement au pembrolizumab en monoth\u00e9rapie chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/a-study-of-belzutifan-lenvatinib-pembrolizumab-versus-lenvatinib-pembrolizumab-for-patients-with-advanced-kidney-cancer\/\">Une \u00e9tude sur une combinaison de belzutifan, de lenvatinib et de pembrolizumab comparativement \u00e0 une combinaison de lenvatinib et de pembrolizumab, chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space][vc_column_text]<strong>POUR LES PATIENTS QUI ONT EU DE TRAITEMENTS M\u00c9DICAMENTEUX ANT\u00c9RIEURS<\/strong><\/p>\n<ul>\n<li><a href=\"\/trial\/a-study-of-belzutifan-lenvatinib-versus-cabozantinib-alone-for-patients-with-advanced-kidney-cancer\/\">Une \u00e9tude sur le belzutifan en combinaison avec le lenvatinib comparativement au cabozantinib en monoth\u00e9rapie chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/a-study-of-different-immune-and-targeted-therapies-for-2nd-line-or-higher-treatment-of-kidney-cancer-substudy-03b\/\">Une \u00e9tude sur diverses th\u00e9rapies cibl\u00e9es et immunoth\u00e9rapies pour le traitement de deuxi\u00e8me\u00a0intention (ou de cycles subs\u00e9quents) du cancer du rein. (Sous-\u00e9tude 03B)<\/a><\/li>\n<\/ul>\n<p>\u00a0<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_empty_space][vc_column_text]POUR LES PATIENTS QUI N&rsquo;ONT PAS EU DE TRAITEMENTS M\u00c9DICAMENTEUX ANT\u00c9RIEURS Une \u00e9tude sur une combinaison de belzutifan et de pembrolizumab comparativement au pembrolizumab en monoth\u00e9rapie chez des patients atteints d\u2019un cancer du rein avanc\u00e9 [\/vc_column_text][vc_column_text] Une \u00e9tude sur une combinaison de belzutifan, de lenvatinib et de pembrolizumab comparativement \u00e0 une combinaison de lenvatinib et [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"year-of-the-new":[54],"class_list":["post-1581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee","year-of-the-new-54"],"_links":{"self":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/comments?post=1581"}],"version-history":[{"count":1,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1581\/revisions"}],"predecessor-version":[{"id":1582,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1581\/revisions\/1582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media\/1107"}],"wp:attachment":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media?parent=1581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/categories?post=1581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/tags?post=1581"},{"taxonomy":"year-of-the-new","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/year-of-the-new?post=1581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}